The thought unsettled her, and she still had a frown on her face when Dan came through the door a few moments later. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.Which by default made Sophie a part time wife. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2022, as filed on. and its subsidiaries, may ultimately prove to be incorrect.
considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. This document contains forward-looking statements for Knight Therapeutics Inc. For more information about Knight Therapeutics Inc., please visit the company's web site at or. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Replay : An archived replay will be available for 30 days at. Media Player is required to listen to the broadcast.
Telephone : Toll Free: 1-85 or International 1-41 Knight cordially invites all interested parties to participate in this call. Following the release, Knight will hold a conference call and audio webcast. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2023 financial results on Thursday, prior to market opening. MONTREAL, (GLOBE NEWSWIRE) - Knight Therapeutics Inc. ( MENAFN- GlobeNewsWire - Nasdaq) English French
0 kommentar(er)
